Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
Ng'at ma kwedo weche mag thieth
Websaitni olos mondo okony ji ng'eyo weche mag thieth, to ok mondo okonygi ng'eyo kaka ginyalo tiyo gi yore mag thieth.
Weche mochiw ok onego oti kodgi e fwenyo kata thiedho tuwo moro, kendo jogo madwaro ng'eyo kaka ginyalo thiedho tuwo moro, onego owuo gi laktar molony.
Ng'e ni neural net ma chiwo dwoko mag penjo, ok en makare ahinya sama iwuoyo kuom kwan mag ji, kaka kwan mar joma nigi tuwo moro.
Kinde duto many paro mar laktar kata ng'at machielo molony e weche thieth e wi tuwo moro. Kik iket kiawa kuom paro mar laktar kata duoko chien kwayo mar thieth nikech gimoro ma isomo e websaitni. Kapo ni iparo ni inyalo bedo gi chandruok mar thieth, luong 911 kata dhi e od thieth machiegni mapiyo. Onge tudruok moro amora e kind laktar gi jatuwo ma yudore e websaitni kata e tiyo kode. BioMedLib kata jotichne, kata ng'ato ang'ata ma konyo e websaitni, ok nyal chiwo paro moro amora, kata ma ok ong'ere, e wi weche ma yudore e websaitni kata e tiyo kode.
Ng'eyo ni ng'ato nigi ratiro mar timo gik moko
Digital Millennium Copyright Act mar 1998, 17 U.S.C. § 512 (the DMCA) chiwo yore mag kony ne joma nigi ratiro mag ndiko ma paro ni weche ma yudore e Intanet ketho ratiro ma gin-go kaluwore gi chike mag ndiko mag piny Amerka.
Kapo ni iyie gi adiera ni weche moro amora ma yudore e websait marwa kata e tijewa ketho ratiro ma in-go mar ndiko weche, in (kata ng'at mochung'ne) inyalo oronwa barua ka ikwayo ni ogol weche ma yudore e websaitno, kata mondo ogeng' ng'ato kik yudgi.
Weche ma ng'ato onego owach nyaka oor e yo mondik kokalo kuom e-mail (ne "Contact" e wi adres mar e-mail).
DMCA dwaro ni ng'eyo ma in-go kuom ketho chik mar copyrights oting'o weche maluwogi: (1) ler mar tij copyrights ma ikwano ni oketho; (2) ler mar weche ma ikwano ni oketho chik mar copyrights kod weche moromo mondo okonywa ng'eyo kama wechego nitie; (3) weche mag tudruok kodi, moriwo adresni, namba mar simo kod adres mar email; (4) weche ma in-go manyiso ni in gi yie maber ni weche ma ondik e yo ma ikwedo ok oyie gi jal ma nigi ratiro mar copyrights, kata gi ng'at mochung'ne, kata gi chik moro amora;
(5) weche ma in iwuon iwacho, ma iketo e bwo buch kuong'ruok, ni weche manie kalatasno gin adier, kendo ni in gi teko mar tiyo gi ratiro mag ndiko ma ji wacho ni oketh;
(6) kod signature mar ng'at ma nigi ratiro mar timo gik moko, kata ng'at ma nigi ratiro mar timo gik moko e lo ng'at ma nigi ratiro mar timo gik moko.
Ka ok iketo weche duto monyis malo kae, mano nyalo miyo idonj e kesno bang'e.
Wuo gi ng'at machielo
Ka in gi penjo kata paro moro amora, yie iornwa e-mail.
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Chiegni ni
BioMedLib tiyo gi kompyuta ma tiyo gi masinde (ma iluongo ni machine-learning algorithms) e loso penjo gi dwoko.
Ne wachako gi buge milion 35 mag weche thieth miluongo ni PubMed/Medline. Bende, ne wachako gi buge mag RefinedWeb.
